Category Archives: Liver-brain Axis

Circadian rhythms and the liver

Costa R, Mangini C, Domenie E, Zarantonello L, Montagnese S Liver Int This narrative review briefly describes the mammalian circadian timing system, the specific features of the liver clock, also by comparison with other peripheral clocks, the role of the liver clock in the preparation to food intake, and its relationship with energy metabolism. It […]

Hyperammonaemia disrupts daily rhythms reversibly by elevating glutamate in the central circadian pacemaker

Granados-Fuentes D, Cho K, Patti GJ, Costa R, Herzog E D, Montagnese S Liver Int Patients with cirrhosis exhibit features of circadian disruption. Hyperammonaemia has been suggested to impair both homeostatic and circadian sleep regulation. Here, we tested if hyperammonaemia directly disrupts circadian rhythm generation in the central pacemaker, the suprachiasmatic nuclei (SCN) of the […]

Hepatic encephalopathy

Häussinger D, Dhiman RK, Felipo V, Görg B, Jalan R, Kircheis G, Merli M, Montagnese S, Romero-Gomez M, Schnitzler A, Taylor-Robinson SD, Vilstrup H Nat Rev Dis Primers Illustrated summary of the article Full text

New Therapies of Liver Diseases: Hepatic Encephalopathy

Mangini C, Montagnese S J Clin Med Hepatic encephalopathy (HE) is a common complication of advanced liver disease which has profound implications in terms of the patients’ ability to fulfil their family and social roles, to drive and to provide for themselves. Recurrent and persistent HE is still a serious management challenge, translating into a […]

Management of the major complications of cirrhosis: Beyond guidelines

Garcia-Pagan JC, Francoz C, Montagnese S, Senzolo M, Mookerjee RP Journal of Hepatology Along with a growing understanding of the pathophysiology of cirrhosis and its complications, new therapies and management strategies have emerged in recent years. Many of these advances have helped inform the current EASL clinical practice guidelines1 on the management of some of […]

A pilot study of Golexanolone, a new GABA-A receptor modulating steroid antagonist, in patients with covert hepatic encephalopathy

Montagnese S, Lauridsen M, Vilstrup H, Zarantonello L, Lakner G, Fitilev S, Zupanets I, Kozlova I, Bunkova E, Tomasiewicz K, Berglund JE, Rorsman F, Hagström H, Kechagias S, Ocklind CE, Mauney J, Thunarf F, Mokhatarani M, Bäckström T, Doverskog M, Lins LE, Månsson M, Samuelson P, Nilsson D, Schalling M, Johansson M, Arlander E, Scharschmidt […]